Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
25 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14 nov. 2024 16h15 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
06 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
05 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
29 oct. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference